Recent Articles from Investor Brand Network

BluSky AI (OTCID: BSAI) announced the launch of a Regulation A+ offering aimed at enabling individual and accredited investors to participate in the company’s planned expansion of its distributed AI infrastructure network, with a minimum investment of $1,000. Proceeds are intended to support development of BluSky AI’s modular AI Factory footprint across the United States, including expansion of its Neocloud compute capacity designed to serve growing demand for large-scale AI training and inference workloads.

American Fusion (OTC: AMFN) provided an update on recent strategic engagements in Washington, D.C., where the company discussed potential applications for its Texatron(TM) Fusion Engine(TM) platform across defense, infrastructure and national energy resilience initiatives. The company also outlined corporate progress, including anticipated Form 10 effectiveness, advancement of its Rule 15c2-11 quotation application, pursuit of OTCQB qualification and continued development of its 5MW Texatron pre-production unit as it advances commercialization and capital markets objectives.

NextPlat (NASDAQ: NXPL, NXPLW) reported improved first-quarter 2026 operating results as ongoing turnaround initiatives drove stronger margins and reduced losses despite lower year-over-year revenue. The company posted quarterly revenue of $9.9 million, a record gross margin of 35%, and a 42% reduction in net loss attributable to common stockholders to approximately $1.1 million, ending the quarter with $11 million in cash and no unsecured debt as management targets positive operating income in the second half of 2026.

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating health innovations, announced it will implement a 1-for-27 reverse stock split of its common stock, effective at the opening of trading on the Nasdaq Capital Market on May 18, 2026. The reverse split is intended to bring the company into compliance with Nasdaq’s minimum bid price requirement, reducing outstanding common shares from approximately 13.8 million to about 510,123, with the stock continuing to trade under the symbol ADTX.

As major technology companies pour billions into AI, two of the sector’s biggest names are increasingly turning to overseas debt markets to support rising costs tied to the fast-moving AI race.

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

Oncotelic Therapeutics (OTCQB: OTLC) announced its featured placement in a BioMedWire editorial focused on emerging CNS drug delivery technologies addressing challenges in Alzheimer’s disease and biodefense research. The editorial highlights the company’s proprietary intranasal nose-to-brain delivery platform, designed to bypass the blood-brain barrier and enable direct therapeutic delivery to the central nervous system, reflecting growing interest in advanced drug delivery approaches for neurological treatment.

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.

Chinese authorities are implementing regulations to formalize electric vehicle battery recycling markets as informal operations have captured roughly 70% of retired battery volumes, creating safety and environmental concerns. New EV battery recycling rules would require end-of-life batteries to remain with vehicles through authorized recycling channels, rather than entering unregulated networks where small operators disassemble and resell components.

New research funded by the NIH has uncovered a link between androgens in men and brain tumors. The preclinical study found that men with low levels of testosterone tended to have shorter survival times when diagnosed with glioblastoma when compared to those that had higher levels of this male sex hormone.

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements.

Growing demand for artificial intelligence sparked gains across three corners of the technology sector on Thursday, May 8, highlighting how investment tied to AI is expanding beyond graphics processors and into the wider digital infrastructure ecosystem.

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement.

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising.

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results while outlining progress in its strategic transformation toward an acquisition-driven growth model focused on clinical-stage neurology and oncology assets. Following quarter end, the company strengthened its balance sheet with a $22.5 million private placement, which, together with existing cash, is expected to support operations beyond 12 months as CNS pursues asset acquisitions and explores out-licensing opportunities for its legacy glioblastoma programs.

This article has been disseminated on behalf of Trilogy Metals Inc. and may include paid advertising.

Kairos Pharma (NYSE American: KAPA) announced it has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award highlights the company’s work in advancing cancer therapeutics designed to address treatment resistance, underscoring Kairos’ focus on extending the effectiveness of existing cancer therapies through innovative drug resistance-targeting approaches.

BOXABL and FG Merger II Corp. (NASDAQ: FGMC) announced that the U.S. Securities and Exchange Commission has declared effective the companies’ joint registration statement on Form S-4 related to their proposed business combination, marking a significant milestone in BOXABL’s path to becoming a publicly traded company. Shareholder meetings to approve the transaction are scheduled for June 9, 2026, with closing expected shortly thereafter, subject to customary conditions, after which the combined company is expected to trade on Nasdaq under the ticker symbol BXBL.

Tonix Pharmaceuticals (NASDAQ: TNXP) announced a poster presentation at ISPOR 2026 highlighting findings from a retrospective cohort study analyzing U.S. claims data from adults with fibromyalgia between April 2021 and April 2024. The presentation will feature real-world insights related to fibromyalgia treatment, following the FDA approval of TONMYA(R) in August 2025 and its subsequent U.S. commercial launch in November 2025.

This article has been disseminated on behalf of G Mining Ventures Corp. and may include paid advertising.

This article has been disseminated on behalf of New Pacific Metals Corp. and may include paid advertising.

HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform and related growth initiatives.

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising.

The cannabis industry has spent years debating what the eventual rollback of Section 280E could mean for businesses operating legally under state law. Tax professionals have largely agreed on one point: if marijuana is moved to a lower federal drug classification, any tax relief would likely apply only going forward.

Forward Industries (NASDAQ: FWDI), focused on building and managing a large-scale Solana (SOL) treasury, recently appointed Mark Brazier as its new CFO. “In his role as CFO, Brazier will oversee Forward’s financial operations, capital structure, financial reporting, capital markets activities, and more, as Forward Industries continues to operate and grow as the worlds-largest publicly traded Solana treasury company,” reads a recent article.

Wearable Devices (NASDAQ: WLDS) announced the launch of Mudra Pro, a next-generation wearable neural sensing platform designed for developers, researchers, enterprise innovation teams and technology partners building AI, XR and human-machine interaction applications. The wrist-worn platform combines synchronized electromyography, photoplethysmography and inertial measurement sensors with embedded processing, sensor fusion and low-latency Bluetooth communication to support physiological state estimation, intent decoding, behavioral analytics and rapid prototyping, with the company positioning the product as a key outcome of its ai6 Labs initiative focused on AI-native wearable computing and next-generation human-computer interaction.

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

Oncotelic Therapeutics (OTCQB: OTLC), alongside Sapu Nano, announced that the first patient has been dosed in the Phase 1b clinical trial evaluating Sapu003, an investigational intravenous Deciparticle(TM) formulation of everolimus for patients with advanced mTOR-sensitive solid tumors. The open-label, dose-escalation study is designed to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity across patient cohorts including HR-positive/HER2-negative breast cancer and multiple additional tumor types, with Sapu003 developed as a weekly IV formulation intended to address limitations associated with oral everolimus delivery, including variable absorption and dose-limiting toxicity.

As global energy markets continue searching for long-term supply security outside traditional producing regions, Greenland is emerging as a frontier attracting renewed attention from explorers and investors alike. Greenland (NASDAQ: GLND), a recently formed energy exploration company focused on Greenland’s hydrocarbon potential, has taken a key step toward advancing its Arctic strategy with a newly announced strategic agreements, securing advanced rig capacity and logistics for its planned onshore oil exploration program.

This article has been disseminated on behalf of Canamera Energy Metals Corp. and may include paid advertising.

As major technology companies pour billions into AI, two of the sector’s biggest names are increasingly turning to overseas debt markets to support rising costs tied to the fast-moving AI race.

As the U.S. midterm elections approach, a new and unusual force is shaping political conversations online: AI-generated influencers. These digital characters, designed to look like real people, are increasingly appearing across social media platforms such as TikTok, Instagram, and Facebook, where they promote Donald Trump and his political message while attacking his opponents.

The Pentagon is taking steps to shield the F-35’s encryption systems from the growing threat posed by quantum computing . A contract notice published May 6, 2026, by the F-35 Joint Program Office signals the shift to quantum computing-proof encryption. The military is moving to future-proof one of the jet’s core security systems before quantum computing advances enough to break current encryption.

Early this week, the price of silver jumped by just over 6% to reach $85.30 an ounce. This came as markets awaited the summit due to be held in Beijing between President Trump and Xi Jinping of China. We unpack why markets reacted in this way in anticipation of the first visit by a sitting U.S. president to China in almost a decade.

AINewsWire Editorial Coverage : The nature of modern conflict is being fundamentally rewritten, driven by the explosive proliferation of cheap, mass-produced drones that are upending the economics of warfare. In war-torn setting such as Ukraine, millions of low-cost systems, often assembled in small workshops or adapted from off-the-shelf commercial hardware, are now performing functions once only sophisticated aircraft and expensive precision munitions could do. However, while drone hardware has grown abundant and affordable, a glaring constraint has surfaced: The vast majority of these systems lack the intelligence needed to operate independently in contested environments. GPS jamming, electronic warfare and the continuous requirement for human control expose a widening gap between what drones are capable of and what they need to be capable of to remain operationally relevant on a scale. Defense leaders are realizing that the next chapter of this revolution will not be written by better hardware alone but by better software, the intelligence layer that delivers autonomy, navigation and targeting precision without depending on systems that adversaries have learned to disrupt. SPARC AI Inc. (OTC: SPAIF) ( Profile ) is operating within this space, creating a software-only platform meant to equip any drone, regardless of cost or manufacturer, with GPS-denied navigation and precision targeting capability. SPARC AI operates alongside a broader cohort of companies active in the drone, AI, and defense-tech space, including Swarmer Inc. (NASDAQ: SWMR), Unusual Machines (NYSE American: UMAC), Draganfly Inc. (NASDAQ: DPRO) and…

BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifying. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) ( Profile ) is taking a distinctive approach: harnessing artificial intelligence (“AI”) and voice analysis to predict impairment from brief speech recordings. By treating the human voice as a window into underlying physiological and cognitive states, MindBio is focused on building a platform capable of detecting intoxication across a wide variety of substances in real time. This approach addresses a meaningful gap in existing detection technology and reflects a larger move toward AI-powered, noninvasive diagnostics with the potential to reshape how enforcement, employers and health systems identify and respond to impairment. MindBio is part of a broader group of companies working at the crossroads of health and AI, including Spectral AI Inc. (NASDAQ: MDAI), Nano-X Imaging Ltd. (NASDAQ: NNOX), NVIDIA Corporation (NASDAQ: NVDA) and…

BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (“BBB”), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer’s disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine’s most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct, targeted access to the central nervous system (“CNS”). Oncotelic has developed a proprietary intranasal nose-to-brain (“N2B”) system capable of rapidly shuttling therapeutics to the brain, a signal of growing industry consensus that delivery innovation, not merely drug discovery, will drive the next wave of breakthroughs in CNS medicine. Oncotelic joins a group of leading biopharma companies working in the biopharmaceutical and advanced therapeutics space, including Amgen Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV) and…

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) ( Profile ), which through its subsidiary GlucaPharm Inc. is developing a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history. SureNano is one of the emerging microcap companies active in the GLP-1 space, operating alongside established leaders including Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Viking Therapeutics Inc. (NASDAQ: VKTX) and…

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising.

Kairos Pharma (NYSE American: KAPA) announced that CEO and Chairman Dr. John Yu will present at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT at the Luxe Sunset Boulevard Hotel in Los Angeles, where he will provide an update on the company’s clinical program and partnering activities.

This article has been disseminated on behalf of Canamera Energy Metals Corp. and may include paid advertising.

Oncotelic Therapeutics (OTCQB: OTLC) was featured in BioMedWire editorial coverage examining the growing urgency around effective central nervous system drug delivery, with the company highlighted for its proprietary intranasal nose-to-brain delivery platform designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain. The editorial points to rising global Alzheimer’s cases and increased biodefense focus as major catalysts driving demand for faster, more targeted CNS delivery technologies, positioning Oncotelic’s platform-based approach as part of a broader shift toward delivery innovation as a critical determinant of therapeutic success.

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial biotechnology company, announced that its management team will participate in two upcoming investor conferences in May 2026: the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.’s Annual Virtual Healthcare Conference on May 20.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced a definitive agreement for the purchase and sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share in a registered direct offering expected to generate approximately $4.4 million in gross proceeds. The company also announced a concurrent private placement of unregistered warrants and said it plans to create an independent business entity composed of its AI platform, withZeta.ai, and related technologies and personnel.

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

A newly released federally backed study suggests that many older Americans are turning to cannabis not for recreation, but in search of relief after struggling with traditional medical treatments.

Titan Partners, a division of American Capital Partners, has appointed Scott Buck, Kyle Bauser, Ph.D., and Adam Kelsey, CFA, to significantly expand its equity research platform across technology, healthcare, and energy, power and infrastructure. The three analysts bring more than 40 years of combined middle-market equity research experience, strengthening Titan’s sector-focused research capabilities as the firm continues to build its investment banking platform focused on underfollowed small- and mid-cap public companies.

AI Maverick Intel (OTC: AIMV) announced the issuance of 76.5 million common shares to HEAL Group Holdings as the initial tranche of consideration under the companies’ Right of First Refusal Agreement dated Feb. 11, 2026, as AIMV advances its proposed acquisition of HEAL Access Canada Inc. The company said the total consideration tied to the transaction has been adjusted from 120 million to 100 million AIMV common shares, with the parties continuing toward a definitive agreement, while also noting plans to pursue an uplisting to the OTCQB Venture Market as part of its broader capital markets strategy.

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising.

This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising.

Bullish (NYSE: BLSH) has entered into a definitive agreement to acquire Equiniti, the parent company of Notified and a global transfer agent and shareholder services provider, in a transaction valued at $4.2 billion. The acquisition is designed to position Bullish at the forefront of blockchain-native capital markets infrastructure by combining its institutional digital asset platform with Equiniti’s regulated transfer agent capabilities, which support nearly 3,000 public companies and more than 20 million verified shareholders.

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising.

Pairing solar and wind with battery storage already delivers electricity at prices that match new coal and beat new gas costs across much of the world, according to a recent International Renewable Energy Agency report . The findings address one of the most enduring objections to renewable power: that intermittent generation makes clean energy unsuitable as a reliable primary source.

Gold’s behavior in 2026 has surprised many investors. Traditionally, geopolitical conflict in the Middle East sends investors rushing into safe-haven assets, pushing gold prices higher. But during the current Iran conflict, the opposite has happened . Each major escalation has triggered gold selloffs, while reports of ceasefires or peace negotiations have sparked rallies.

A new survey of German car industry managers suggests the sector is further into its electric vehicle transition than public debate tends to imply, with a small group of slower-moving firms distorting the wider picture and potentially dragging down the broader shift. The research was carried out jointly by the University of Sussex and the Fraunhofer Institute for Systems and Innovation Research, drawing on responses from 74 industry managers gathered toward the end of 2025.

The NHS in England is rolling out a treatment upgrade under which thousands of patients with cancer will now receive a one-minute injection of the immunotherapy pembrolizumab instead of having the drug administered via infusion as has been the case in the past. The jab slashes the administration time from hours to just a minute or two.

An analysis of the semiconductor stocks performing exceptionally well reveals that all these companies provide a product that is regarded as a bottleneck in the AI boom . Several companies help to illustrate this insight.

German automaker Porsche has announced plans to cut more than 500 jobs as the company faces growing financial pressure and slowing demand for electric vehicles. The move is part of a wider restructuring effort aimed at helping the luxury carmaker focus on its main business operations during a difficult period for the global auto industry.

Major crypto exchanges are reportedly stepping up efforts to influence legislation in Washington, seeking changes to a proposed market-structure measure that could significantly affect how digital assets are traded in the U.S.

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

Lunai Bioworks (NASDAQ: LNAI) is the plaintiff in a federal securities fraud lawsuit filed in Delaware by national law firms Dickinson Wright and Fox Rothschild, alleging that unidentified “naked” short sellers engaged in a coordinated scheme to manipulate trading in the company’s common stock. The complaint alleges repeated violations of SEC Regulation SHO, including failures to deliver shares reaching as high as 234.6 times the maximum baseline daily rate and periods in which failures to deliver allegedly represented 81.6% of the company’s total outstanding shares.

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising.

Tonix Pharmaceuticals (NASDAQ: TNXP) reported first-quarter 2026 financial results while highlighting continued commercial momentum for TONMYA, its recently launched fibromyalgia treatment, and advancement across its clinical pipeline. The company said TONMYA, the first new fibromyalgia medicine in 15 years, has shown growth in prescriptions, prescribers, refills and patient access since its November 2025 launch, with a recently announced managed care agreement expanding potential coverage to approximately 35 million U.S. commercial lives, while pipeline progress included positive Phase 1 data for TNX-4800, a Lyme disease prevention candidate, and plans to begin a Phase 2 study of TONMYA in major depressive disorder later this year.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and machine learning platforms.

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in a BioMedWire editorial examining emerging breakthroughs in central nervous system drug delivery and the growing market opportunities tied to overcoming the blood-brain barrier. The editorial highlights Oncotelic’s proprietary intranasal nose-to-brain delivery platform, which is designed to enable rapid, targeted therapeutic access to the brain, positioning the company within a broader industry effort to advance next-generation treatments for neurological disease, biodefense applications and other CNS-related conditions.

In a blog post by Daniel Azoulai, Qdrant highlighted how Sapu , an early-stage biopharmaceutical company developing treatments for hard-to-treat cancers, uses Qdrant Cloud infrastructure to power an AI research platform capable of indexing and querying all 28 million PubMed abstracts in a single searchable collection, helping accelerate biomedical discovery workflows.

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

A new report from congressional researchers is shedding light on what the Trump administration’s move to reclassify cannabis could mean for the industry, while also outlining the limits of the policy shift under federal law.

Pershing Square USA (NYSE: PSUS) and Pershing Square Inc. (NYSE: PS) announced the closing of their combined initial public offerings and previously announced combined private placement, generating gross proceeds of $5 billion for PSUS before deducting sales loads, placement fees and offering expenses. The PSUS shares and PSI shares began trading on the New York Stock Exchange on April 29, 2026, under the symbols PSUS and PS, respectively.